Vertex Pharmaceuticals (VRTX) EBIT Margin (2009 - 2026)

Vertex Pharmaceuticals' EBIT Margin history runs 18 years deep, the most recent figure standing at 38.1% for Q1 2026.

• On a quarterly basis, EBIT Margin rose 1536.0% year-over-year to 38.1% in Q1 2026; TTM through Mar 2026 was 38.31%, a 4500.0% increase from a year earlier, with the FY2025 full-year figure at 34.77%, up 3689.0% from the prior year.
• EBIT Margin climbed to 38.1% in Q1 2026 per VRTX's latest filing, from 37.8% in the prior quarter.
• Across five years, EBIT Margin topped out at 50.37% in Q2 2022 and bottomed at 132.85% in Q2 2024.
• The 5-year median for EBIT Margin is 39.26% (2023), against an average of 29.95%.
• Across the five-year window, EBIT Margin slumped 17402 bps in 2024 and soared 17168 bps in 2025, its largest moves.
• Year by year, EBIT Margin stood at 44.88% in 2022, then slipped by 13 bps to 39.26% in 2023, then slipped by 10 bps to 35.23% in 2024, then gained by 7 bps to 37.8% in 2025, then increased by 1 bps to 38.1% in 2026.
• Per Business Quant, the three latest VRTX EBIT Margin figures stand at 38.1% (Q1 2026), 37.8% (Q4 2025), and 38.56% (Q3 2025).